From the time I originally became involved with OWCP they've said they're taking a dual path on practically every product. The report seems to differ from this approach.
I previously indicated that I thought they might wait for at least some efficacy information, but that could be available in Phase 2, and frankly if the Phase 2 wasn't blinded, they wouldn't even need to finish that as long as efficacy was demonstrated early in the trial. I.E. the cream, and if the same approach was taken with the sublingual tablet, both could be in the marketplace with efficacy demonstrated this year. The language in the report seems not to say they'll take this approach, clearly they need to reestablish just what their intent is.
Gary
News 
Market Data 
Discover 
AI
